Activity of faropenem against cephalosporin-resistant Enterobacteriaceae

Shazad Mushtaq, Russell Hope, Marina Warner, David M Livermore

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


There is a need for new oral agents active against extended-spectrum beta-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporin-resistant bacteria.
Original languageEnglish
Pages (from-to)1025-30
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Issue number5
Publication statusPublished - May 2007


  • Anti-Bacterial Agents
  • Cephalosporin Resistance
  • England
  • Enterobacteriaceae
  • Humans
  • Microbial Sensitivity Tests
  • beta-Lactams

Cite this